The paired-box (PAX) genes encode a family of nine wellcharacterized paired-box transcription factors, with important roles in development and disease. Although PAX genes are primarily expressed in the embryo, constitutive expression promotes tissue hyperplasia. Rare tumorspecific mutations of PAX genes implicate an oncogenic role, and persistent PAX expression characterizes several tumors. Yet, a cancer-wide analysis of PAX gene expression to investigate a general role for PAX genes has not been performed. We analysed the pattern and requirement for PAX gene expression in a panel of common cancer cell lines. Very frequent PAX gene expression was identified in tumor cell lines, including lymphoma, breast, ovarian, lung, and colon cancer. In addition, the PAX2 gene was frequently expressed in a panel of 406 common primary tumor tissues. Apoptosis was rapidly induced in ovarian and bladder cancer cell lines following RNA interference to silence PAX2 expression, despite concomitant TP53 and/or HRAS mutations. These data suggest that PAX genes are frequently expressed in cancer, and that endogenous PAX gene expression is required for the growth and survival of cancer cells.
Introduction
The PAired-boX (PAX) gene family has been well characterized in both human (PAX) and mouse (Pax), and consists of nine genes (Dahl et al., 1997; Chi and Epstein, 2002) . Each of the PAX genes encodes a transcription factor containing a paired-box DNAbinding domain, with or without octapeptide and/or homeodomains (Dahl et al., 1997) . Subclassification of the PAX genes into subgroups (PAX1/PAX9, PAX2/ PAX5/PAX8, PAX3/PAX7, PAX4/PAX6) on the basis of sequence correlates with expression patterns in developing embryonic tissues (Chi and Epstein, 2002) .
In each of these tissues, the PAX genes specify positional information in the developing embryo. The PAX genes are tightly regulated in both temporal and spatial expression patterns, and expression is observed primarily during fetal development, with the genes being switched off during latter phases of terminal differentiation of most structures. This pattern is maintained in the mature organism. However, in a few adult tissues, PAX genes are expressed in a restricted fashion (Kozmik et al., 1993; St-Onge et al., 1997; Eccles, 1998) . In contrast, abnormal cell growth and proliferation is associated with high levels of PAX gene expression in several diseases occurring in otherwise terminally differentiated tissues (Bernasconi et al., 1996; Winyard et al., 1996; Murer et al., 2002) .
Haploinsufficiency of PAX2, PAX3, and PAX6 genes cause dysmorphic syndromes with developmental abnormalities (Glaser et al., 1992; Jordan et al., 1992; Tassabehji et al., 1992; Sanyanusin et al., 1995) . In affected mutant tissues, dysmorphogenesis is associated with increased apoptosis in cells that normally express the PAX gene (Borycki et al., 1999; Ostrom et al., 2000; Porteous et al., 2000; Torban et al., 2000; van Raamsdonk and Tilghman, 2000) . Conversely, deregulated expression of PAX2 blocks caspase 2-induced apoptosis in HEK293 cells, suggesting a role for PAX2 in cell survival. Yet, the continuous expression of PAX genes is not required at late stages of differentiation or following terminal differentiation of cells. For example, PAX2 expression must be switched off for completion of epithelial differentiation in the kidney (Dressler et al., 1993) . Persistent expression of PAX genes in terminally differentiated tissues is associated with a blockage in tissue differentiation and hyperplasia (Dressler et al., 1993; Morrison et al., 1998b) .
Chromosomal translocations involving PAX3, PAX5, PAX7 or PAX8 genes in alveolar rhabdomyosarcoma, B-lymphoid malignancies, or thyroid cancer, respectively, suggest that PAX genes have an oncogenic capacity when constitutively expressed, either as part of a fusion gene, or as a whole gene (Barr et al., 1993; Davis et al., 1994; Morrison et al., 1998a; Kroll et al., 2000; Cazzaniga et al., 2001; Marques et al., 2002) . In addition, PAX genes are persistently expressed in several embryonal tumors (Dressler and Douglass, 1992; Eccles et al., 1992 Eccles et al., , 1995 Bernasconi et al., 1996) and adult tumors (Fabbro et al., 1994; Gnarra and Dressler, 1995; Stuart et al., 1995b; Scholl et al., 2001; Silberstein et al., 2002) , and reduced survival has been observed in rhabdomyosarcoma or melanoma cell lines following treatment with PAX3 antisense oligonucleotides (Bernasconi et al., 1996; Scholl et al., 2001 ). Yet, constitutive expression of PAX5 is not sufficient to induce transformation of the mouse neuroectoderm (Steinbach et al., 2001) . It is therefore unclear whether PAX gene expression plays a significant role in cancer in general, and it is not known to what extent PAX genes are expressed in cancer.
To investigate the frequency and significance of PAX gene expression in cancer, we characterized PAX gene mRNA levels in 54 common cancer cell lines, including 51 cell lines of the NCI-60 cell line panel. Approximately 90% of the cancer cell lines expressed PAX genes, while a high proportion of primary tumors, including breast, ovarian, lung, colon, prostate, and lymphoma, expressed PAX2. The role of PAX gene expression in several different cancer types was investigated in melanoma (PAX3), and in ovarian and bladder cancer cell lines (PAX2). Both PAX2 and PAX3 were functionally important in the cancer cell lines, as rapid induction of apoptosis was observed following treatment of cancer cells with either siRNA, or antisense oligonucleotides designed to inhibit PAX2 or PAX3 expression. These data suggest that endogenous PAX gene expression in cancer is common, and is required for the growth and survival of many cancer types.
Results and discussion
Melanoma cell lines depend on PAX3 for survival Scholl et al. (2001) previously analysed five melanoma cell lines, and showed that treatment with a PAX3 antisense oligonucleotide resulted in induction of apoptosis and reduced cell survival in the melanoma cell lines specifically expressing PAX3. To confirm the requirement for PAX3 in melanoma cell survival, we transfected two melanoma cell lines from the NCI-60 cell line panel, M14 (TP53 mutant) and UACC-62 (TP53 wildtype), with PAX3 antisense oligonucleotide, as previously described (Scholl et al., 2001) . Treatment of the cell lines with the PAX3 antisense oligonucleotides led to significantly decreased cell growth, and increased annexin V staining in flow cytometric analysis, suggesting that treated cells underwent apoptosis when exposed to the antisense oligonucleotide. Treatment with sense PAX3 oligonucleotide resulted in no significant change in the cell survival (Figure 1 ). Annexin V positive staining was detected in 45% of UACC-62 cells and 18% of M14 cells 24 h after antisense treatment, but in only 23 and 13% of sense PAX3 oligonucleotidetreated cells, respectively ( Figure 1a ). The induction of apoptosis was rapid, as annexin V staining was detected in the antisense-treated UACC-62 melanoma cells within 12 h after treatment. The proliferation of both UACC-62 and M14 cells was significantly inhibited at 24 h following treatment (Figure 1b) .
PAX genes are frequently expressed in cancer
These experiments confirm that PAX3 is required for the survival of melanoma cell lines, but extending this observation to other PAX genes, and whether PAX genes are expressed frequently in cancer in general, has not been investigated. A comprehensive analysis of gene expression profiles by microarray in the NCI-60 panel did not include PAX genes, although the genes expressed in each cell line were characteristic of the particular tumor type (Ross et al., 2000) . To characterize the approximate frequency with which PAX genes are expressed in a cross-section of common human (4) (Eccles et al., 1992) . We then analysed whether the expression of PAX mRNA, as detected by real-time PCR, was reflected by expression of protein, focusing primarily on PAX2. PAX2 is expressed in several human cancer types (Dressler and Douglass, 1992; Eccles et al., 1992; Gnarra and Dressler, 1995; Silberstein et al., 2002) , and PAX2 expression in several human tumors has been shown previously using an anti-Pax2 antibody (Dressler and Douglass, 1992; Gnarra and Dressler, 1995; Silberstein et al., 2002) . The expression of PAX2 mRNA concurred with the expression of PAX2 protein, as detected by Western blot, in most of the cell lines analysed (Figure 3a , b, and data not shown). However, in several cell lines with detectable PAX2 protein, PAX2 mRNA levels were below the cutoff level of detection by real-time PCR (Figure 3a , b), suggesting that the realtime PCR may have underestimated the true frequency of PAX gene expression. If the cutoff for real-time PCR was changed from 30 cycles to 32 cycles, making the baseline of detection less stringent, then more cell lines that were positive for PAX2 by Western blot were also positive by real-time PCR, but more than 96% of cancer cell lines expressed at least one PAX gene at this level of baseline detection. The mRNA level of eight PAX genes (PAX1-PAX3 and PAX5-PAX9) was analysed using quantitative real-time PCR in 54 cell lines (named on the left side of the figure). The cell lines comprised 51 cell lines of the NCI-60 panel, including brain (Bra), melanoma (Mel), breast (Bre), colon (Col), lung (Lun), leukemia (Leu), ovarian (Ova), prostate (Pro), and renal (Ren) cancer, plus three additional lines (*) comprising EJ bladder carcinoma cells, and P388 and P388/ADR leukemia cells. The relative expression level of PAX mRNA is represented by shading as follows, no expression (white), low (light grey), moderate (medium grey), high (dark grey), very high (black). In the two columns on the right is shown the level of TP53 mRNA expression (Q), and TP53 mutation status (M) for each cell line. Data for the mutation status and expression level for p53 for each cell line were obtained from the website, http:// dtp.nci.nih.gov/mtargets/mt_browse.html, or as reported (Rieger et al., 1995) . The relative TP53 expression level was interpreted as undetectable (white), low (light grey), and high (black). Mutation status is shown as nonmutant (white), and mutant (black) The PAX gene expression patterns in the cell lines did not correlate with expression of other cancer-related genes, including TP53 (Figure 2) or members of the BCL2 superfamily, despite evidence suggesting that regulatory networks of these genes exist in cells (Stuart et al., 1995a; Hewitt et al., 1997; Barton et al., 2000; Margue et al., 2000) . In many of the cancer cell lines in this study, the presence or absence of PAX gene expression did not necessarily match the type of fetal or adult tissues in which PAX genes are normally expressed. In one report, overexpression of PAX6 in human colon and bladder cancers was associated with hypermethylation of exon 5 of the PAX6 gene (Bender et al., 1999; Salem et al., 2000) . However, the precise mechanisms leading to persistent PAX gene expression in cancer are poorly understood.
Dependence of ovarian and bladder cancer cell lines on PAX2 for survival As multiple PAX genes are frequently expressed in cancer, it was pertinent to determine whether multiple members of the PAX gene family are required for survival when expressed in cancer. In previous studies, renal cancer cells exhibited reduced proliferation capacity upon downregulation of PAX2 using an antisense oligonucleotide, although cell survival was not examined (Gnarra and Dressler, 1995) . To determine whether PAX2 is required for cell survival in cancer cell lines, we designed a PAX2 small inhibitory double-stranded RNA (siRNA) and used this to silence PAX2 expression in IGROV1 ovarian cancer cells, which express PAX2 and PAX8, and in EJ bladder carcinoma cells, which express PAX2, PAX6, and PAX8. Following a single transfection of cells with the PAX2 siRNA, we observed a large and sustained inhibition of PAX2 protein expression lasting 7 days (Figure 4a, b) . In EJ cells, PAX2 protein levels returned to normal by day 7, but remained silenced at 7 days in IGROV1 cells. Cell proliferation was strongly inhibited, as an increase in total cell mass in the PAX2 siRNA-treated cultures was inhibited for more than 7 days in both EJ cells and IGROV1 cells in comparison to control treatments following a single treatment with PAX2 siRNA (Figure  4c -e), irrespective of the status of TP53 or HRAS mutations in the cells (Parada et al., 1982; Rieger et al., 1995) (http://dtp.nci.nih.gov/mtargets/mt_browse.html) (Figure 2 ). In contrast, treatment with the PAX2 siRNA did not affect the growth of COS-7 cells, which do not express PAX2 protein (Figure 4e) .
A striking increase in annexin V positive cells was identified in both EJ and IGROV1 PAX2 siRNAtreated cells, but not in COS-7 cells, suggesting that cells In contrast, less than 3% of COS-7 cells underwent apoptosis following treatment. These data suggest that the expression of multiple PAX genes did not interfere with induction of apoptosis following the silencing of PAX2 expression alone. This was unexpected, as several studies have suggested that PAX gene function is redundant to the concurrent expression of other PAX family members (Mansouri and Gruss, 1998; Bouchard et al., 2000) . In contrast, crossregulation and evidence for hierarchical regulation of PAX genes during development (Pfeffer et al., 1998; Borycki et al., 1999) may explain the nonredundant effects of silencing PAX2 expression.
PAX2 is frequently expressed in primary human cancers
To determine whether the expression of PAX genes in the cancer cell lines accurately represents the situation in primary tumors, positive immunoreactivity for PAX2 protein was analysed in 406 primary tumors, representing eight common tumor types ( Figure 6 , Table 1 ). PAX2 was expressed in at least 25% of tumor sections in brain, breast, lymphoma, and ovarian cancer ( Figure 6 ). In each section, PAX2 immunopositive expression was detected in a varying proportion of tumor cells (not shown). The frequency of PAX2 expression in primary tumors was similar to that of PAX2 mRNA expression in the cell lines, except breast cancer in which PAX2 mRNA was observed in none of the cell lines, but PAX2
protein was expressed in 27/68 (40%) primary breast cancer tissues. Silberstein et al. (2002) also found that PAX2 is expressed in approximately 53% of primary breast cancers. The discrepancy in the PAX2 expression between the tumors and the cell lines in this study may simply be a reflection of the particular cell lines in the NCI-60 panel, or that the cells that ultimately give rise to the breast cancer cell lines are not the cells in the tumors that express PAX2. Our results show that PAX gene expression is required for the growth and survival of multiple cancer cell types, and that inhibiting expression of PAX2 or PAX3 genes in cancers leads to the rapid induction of apoptosis. Furthermore, PAX genes are expressed in a high proportion of common human tumors, but only in a limited number of adult tissues (Dahl et al., 1997) . Of particular interest is the expression of PAX2 in a high proportion of breast and ovarian cancers. Our results concur with those of a recent study, which showed PAX2 expression in more than 50% of breast cancers (Silberstein et al., 2002) . PAX2 is also expressed in the tissues of the genital tract (Fickenscher et al., 1993) including oviduct, and PAX2 and PAX8 are frequently expressed in ovarian cancer cell lines. It is likely that overexpression of other members of the PAX gene family also contribute to cancer cell growth and survival in specific types of cancer, since chromosomal PAX genes and cancer cell survival A Muratovska et al rearrangements lead to the translocation of heterologous promoter sequences into the 5 0 regulatory regions of the PAX5 or PAX8 genes, resulting in constitutive expression of the PAX gene mRNA in some lymphomas and thyroid cancer, respectively (Morrison et al., 1998a; Kroll et al., 2000; Cazzaniga et al., 2001) .
Although the constitutive expression of Pax genes in adult tissues may not in itself be oncogenic (Dressler et al., 1993; Steinbach et al., 2001) , the observation that a very high proportion of tumors express PAX genes irrespective of their tissue of origin suggests that PAX gene expression confers a strong advantage to cancer cell growth, and that cancer cells have exploited this expression pattern for tumor progression rather than tumor initiation. Recent studies show that PAX genes are required only at certain stages of tissue development or organogenesis, suggesting that there are cell-specific PAX gene functions (Porteous et al., 2000; Ridgeway and Skerjanc, 2001; Bouchard et al., 2002; Chi and Epstein, 2002) . In relation to this, the immunohistochemical staining patterns of PAX2 expression in primary tumor sections revealed that only a variable fraction of the tumor cells expressed PAX2. This does not necessarily imply that not all cells in a tumor are susceptible to the apoptotic effects of inhibiting PAX2 expression, as it is possible that PAX genes induce the expression of essential autocrine or paracrine survival factors in tumors, and that the silencing of PAX gene expression therefore modulates the expression of these survival factors. The identification of tumor-specific molecules that serve as targets for the development of new cancer drugs is a major goal in cancer research. The results presented here suggest that PAX genes exhibit several attributes that would be expected of a suitable cancer target, including a role in cancer cell survival, and widespread expression in cancer.
Materials and methods
Cell culture, RNA isolation, transfections, and RNAi Cells were grown at 371C and 5% CO 2 in humidified atmosphere, in either RPMI 1640 medium supplemented with 5% inactivated FBS for cell expansion and RNA isolation, or in Dulbecco's modified Eagle's medium supplemented with 10% FBS for transfections. All cell culture media were supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin. RNA was isolated from cell lines using Trizol reagent, according to the manufacturer's instructions (GIBCO-BRL). At 6-24 h before transfection at 60-80% confluency, the cells were trypsinized, diluted 1 : 3 with fresh medium (1-5 Â 10 5 cells/ml) and transferred to 24-well plates (500 ml per well). Cells were either transfected with single-stranded sense or antisense oligonucleotides against human PAX3, or with annealed siRNAs against human PAX2. RNAi transfections contained Lipofectamine 2000 (Invitrogen, 1 ml per well) and 0.50 mg of each PAX2 siRNA and GL2 siRNA duplex per well. Oligonucleotide transfections contained Lipofectin (Invitrogen, 4 ml per well) and 1 mm sense or antisense PAX3 oligonucleotide. Control cell incubations were carried out with Lipofectin or Lipofectamine 2000 only and with media only. After 5-12 h, the transfection medium was replaced with serum-containing medium. Cell incubations were carried out for up to 7 days following transfection with siRNA. Single transfections were shown to be just as efficient as multiple transfections; there was no further change in the level of Pax2 protein expression with multiple transfections, and although there was a slight increase in apoptosis of the cells, this was probably due to toxicity induced by the increased levels of lipofectamine following multiple transfections. PAX2 expression was subsequently detected by Western blotting using a polyclonal antiPax2 antibody (Zymed). Cell proliferation was monitored by the MTT assay (Roche) and cell death was assayed by flow cytometry. For RNAi, 21-nucleotide RNAs were chemically synthesized, de-protected and purified by Dharmacon Research (Lafayette, CO, USA). Complementary short interfering ribonucleotides (siRNAs) targeting human PAX2 mRNA (Accession No. NM_003989.1) were synthesized, corresponding to the coding region 1455-1473 relative to the first nucleotide of the start codon (5 0 -rGrUrCrGrArGrUrCrUrArUrCrUrGrCrArUrCrCTT-3 0 and 5 0 -rGrGrArUrGrCrArGrArUrArGrA rCrUrCrGrArCTT-3). A second set of complementary siRNAs targeting the GL2 luciferase mRNA (Accession No. X65324) was synthesized, corresponding to the coding region 153-173 (5 0 -rCrGrUrArCrGrCrGrGrArArUrArCrUrUrCrGrATT-3 0 and 5 0 -rUrCrGrArArGrUrArUrUrCCrGrCrGrUrArCrGTT-3). The GL2 siRNAs were used as an internal control to test for the specificity of PAX2 siRNAs. For annealing of siRNAs, 35 mm of single strands were incubated in annealing buffer (100 mm potassium acetate, 30 mm HEPES-KOH at pH 7.4, 2 mm magnesium acetate) for 1 min at 901C followed by 1 h incubation at 371C. For oligonucleotide transfections, antisense and sense PAX3 phosphorothioate oligonucleotides were synthesized (Genset, Singapore) corresponding to nucleotides 123-141 of human PAX3 mRNA: antisense (5 0 -GCGTGGTCATCCTGGGGGC-3 0 ), sense (5 0 -GCCCCCAGGATGACCACGC-3 0 ) (Bernasconi et al., 1996) .
Quantitative real-time PCR
First-strand cDNA was produced from 2 mg of random hexamer primed total RNA using reverse transcription reactions (20 ml) containing 15 mm (NH 4 ) 2 SO 4 , 20 mm TrisHCl (pH 8.8), 2 mm MgCl 2 , 0.05% Tween-20, 500 mm dNTPs (Roche), 0.2 mm DTT, 10 mm random hexamer primer (Roche), 1 U DNase I (Roche), 1 U RNasin (Promega), and 200 U Superscript II reverse transcriptase (Life Technologies). Reactions were incubated at 421C for 50 min. Relative quantitation by real-time PCR was carried out using SYBR-green detection of PCR products in real time using either the ABI PRISM 7700 or ABI PRISM 7000 Sequence Detection System (Applied Biosystems Inc.). In each experiment, the human b2 microglobulin (B2 M) housekeeping gene was amplified as a reference standard. Primers for B2 M were B2MF, 5 0 -AGATGAGTATGCCTGCCGTGT-3 0 and B2MR, 5 0 -GCTTACATGTCTCGATCCCACTTA-3 0 . In all real-time PCR experiments, RT and genomic DNA samples were included as negative controls. Template RNAs were treated with DNase I prior to amplification, according to the manufacturer's instructions (Applied Biosystems Inc.). Each real-time PCR reaction (25 ml) contained 2.5 ml of cDNA, 12.5 ml of 2X SYBR Green Master Mix (Applied Biosystems Inc.), including Amplitaq polymerase (PerkinElmer), and primers at a final concentration of 20 mm. Primers for each PAX gene were designed (for technical reasons primers for PAX4 did not efficiently amplify transcripts and so were not used in the analysis) using Primer Express (Applied Biosystems Inc.), and tested empirically for efficiency of amplification using RNA from cell lines known to express the PAX gene of interest. Primers were as follows:
0 . Reactions were prepared in duplicate and heated to 951C for 10 min followed by 40 cycles at 951C for 15 s and 581C for 60 s, with a final incubation at 951C for 15 min. To detect the log phase of amplification, the fluorescence level (quantification of product) was determined at each cycle. The cycle at which the fluorescence reached threshold (CT) was recorded, averaged between duplicates, and normalized to the averaged CT value for B2 M. The normalized values were then subtracted from 30, being a cutoff CT value at which we determined expression from each gene was undetectable, the difference of which was deemed to be related to the expression level of each PAX gene. The relative expression level for each PAX gene in the cell lines was then calculated according to the manufacturer's instructions (Applied Biosystems Inc.). To represent the relative expression level, the following categories were delineated; 0-1 units, no expression (white box), 2-19, low (light grey), 20-199, moderate (medium grey), 200-1999, high (dark grey) , and 42000, very high expression (black).
SDS-PAGE and immunoblotting
Cell samples were lysed in 20 ml loading buffer (50 mm Tris, 4% SDS, 12% glycerol, 2% 2-mercaptoethanol, 0.01% coomassie brilliant blue) and were separated on a 12.5% Tris-glycine gel. Gels were then either fixed and stained with coomassie brilliant blue (0.1% (w/v) coomassie brilliant blue R-250, 45% (v/v) methanol and 10% (v/v) acetic acid), or electrotransfered onto 0.2 m nitrocellulose (100 V, 1 h) in transfer buffer (25 mm TrisHCl, pH 8.3, 192 mm glycine, 20% methanol) and then blocked with 2% (w/v) fat-free milk powder in TBS (5 mm Tris-HCl, pH 7.4, 20 mm NaCl), 0.1% Tween-20. Rabbit antiPax2 polyclonal antibody (Zymed, Cat No. 71-6000) diluted 1 : 1000 in TBS, 0.1% fat-free milk powder, and 0.1% Tween-20 was used for immunodetection with overnight incubation. After 3 Â 10 min washes in TBS, 0.1% Tween-20, horseradish peroxidase-conjugated goat anti-rabbit IgG (1 : 10 000, Biorad) was used as a secondary antibody. The incubation with secondary antibody was for 1 h at room temperature, followed by 3 Â 10 min washes in TBS and visualized by chemiluminescence using a Pierce Super Signal R chemiluminescence substrate with Kodak X-OMATTM AR imaging film.
PAX2 immunostaining
For PAX2 immunostaining, either paraffin-embedded tumor tissues were sectioned at 10 mm and mounted onto l-lysinecoated slides, or tumor tissue array slides (TARP4) were obtained from the National Cancer Institute (Bethesda). Tumor sections were deparaffinized and incubated with polyclonal rabbit primary anti-Pax2 antibody (10 mg/ml) (Zymed, Cat No. 71-6000), or polyclonal rabbit primary anti-thiobutyltriphenylphosphonium (TBTP) antibody (1 : 1000 dilution) (Lin et al., 2002) for 30 min at room temperature in PBS supplemented with 20 mm glycine and 1% bovine serum albumin. Primary antibodies were detected with Vectastain ABC anti-rabbit IgG kit (Vector Laboratories) as described by the manufacturer, followed by incubation with diaminobenzidine (DAB) substrate (Sigma). Negative control incubations using the secondary anti-rabbit IgG antibody from the ABC kit omitting the primary anti-Pax2 antibody were also carried out, and as expected gave negative results, Sections were washed in PBS, counterstained with hematoxylin, dehydrated, and mounted with Permount (Fisher).
MTT assay
Cell proliferation of EJ, IGROV-1, M14, UACC62, and COS-7 cells was measured using the cell proliferation kit I (MTT) supplied by Roche. Cells were seeded in 96-well plates (10 4 cells per well) with 100 ml DMEM containing 10% FBS. Following transfection, as described above, the cells were incubated for 12 h, after which 10 ml of MTT (5 mg/ml in PBS) was added to each well and incubated for 4 h at 371C. The resulting formazan within the cells was dissolved in 100 ml of 10% SDS in 0.01 m HCl. Optical densities were read immediately at 620 nm using a PolarStar Optima microplate reader. This procedure was repeated every 24 h for up to 7 days following treatment.
Flow cytometry
Cells (EJ, IGROV-1, M14, UACC62, and COS-7) grown in 24-well plates were treated with PAX2 siRNAs, PAX3 sense or antisense oligonucleotides, lipofectamine 2000 or lipofectin only or media only as described above. These treatments were carried out for 12, 24, 48, and 72 h, after which the cells were prepared for flow cytometry. Following each incubation period, the medium was collected from the wells (to retain any detached cells) and combined with PBS used to wash the wells twice. The cells were then harvested by trypsinization and combined with the detached cells and PBS. The cells were pelleted at 41C (1000 g, 5 min), washed in PBS twice and resuspended in 100 ml binding buffer (10 mm HEPES/NaOH pH 7.4, 140 mm NaCl, 5 mm CaCl 2 ) supplemented with 2 ml fluorescein annexin-V conjugate (Molecular Probes, OR, USA). The cells were incubated for 15 min on ice in the dark, diluted in 400 ml binding buffer and analysed using a Becton Dickinson fluorescence-activated cell sorter. Apoptotic cell death was quantitated using the Cell-Quest software (Becton Dickinson, San Jose, CA, USA).
